PMID-35717045 – Lutetium-177 DOTATATE Practical Review
Mittra ES. Neuroendocrine Tumor Therapy: 177Lu-DOTATATE. AJR Am J Roentgenol. 2018;211(2):278-285. [Note: Review published 2022 in J Nucl Med Technol; 50(2):102-106.]
Mitjavila M, Jimenez-Fonseca P, Marin-Pozo JF, et al. Lutetium-177 DOTATATE: A Practical Review. J Nucl Med Technol. 2022;50(2):102-106.
Quick Reference
| Property | Value |
|---|---|
| PMID | 35717045 |
| DOI | 10.2967/jnmt.121.263528 |
| Year | 2022 |
| Journal | Journal of Nuclear Medicine Technology |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (review article) |
| Peptide(s) Studied | Lutetium-177-DOTATATE |
Key Findings
- Comprehensive practical review covering patient selection, treatment protocols, dosimetry, and follow-up for 177Lu-DOTATATE PRRT
- Standard treatment protocol: 7.4 GBq (200 mCi) IV every 8 weeks for 4 cycles
- Patient selection requires positive somatostatin receptor imaging (68Ga-DOTATATE PET/CT or OctreoScan)
- Key eligibility criteria: adequate bone marrow reserve, renal function (GFR >30 mL/min), and ECOG performance status 0-2
- Main toxicities: bone marrow suppression (10% grade 3-4), nephrotoxicity (rare but cumulative), and hepatotoxicity in patients with high tumor burden
- Amino acid co-infusion (lysine/arginine) is standard for renal protection during infusion
- Long-term risk of myelodysplastic syndrome/acute leukemia (~2-5% at 5 years)
Study Design
Narrative review synthesizing evidence from NETTER-1, ERASMUS, and institutional experience to provide a practical guide for nuclear medicine physicians and technologists implementing 177Lu-DOTATATE therapy programs.
Limitations
- Narrative review format without systematic search methodology
- Focused on practical implementation rather than comprehensive efficacy analysis
- Some recommendations based on expert opinion and institutional protocols rather than RCT data
Clinical Relevance
This review serves as a practical reference for clinical teams implementing PRRT programs. It covers the entire patient journey from selection through treatment to long-term follow-up, making it valuable for understanding the logistics and safety considerations of peptide receptor radionuclide therapy beyond what is captured in pivotal trial publications.
Related
- Lutetium-177-DOTATATE
- Octreotide
- Cancer Adjunct Therapy
- PMID-28076709 – NETTER-1 Lu-177-DOTATATE for Midgut NETs Phase III
#research #narrative-review #lutetium-177-DOTATATE #evidence-level-V